Upadacitinib Shows Significant Repigmentation in Phase 3 Vitiligo Trials

For millions living with nonsegmental vitiligo, the medical landscape has long been characterized by a lack of systemic options. That reality may be shifting. New results from two phase 3 trials, Viti-Up-1 and Viti-Up-2, suggest that the oral medication upadacitinib could offer a path toward meaningful repigmentation, according to a report in The American Journal of Managed Care® (AJMC®). This data marks the first time a systemic drug has demonstrated this level of efficacy in a placebo-controlled, peer-reviewed clinical setting, potentially opening a new therapeutic lane for a condition that has historically relied on localized topicals or light therapy.

The studies, which enrolled a combined total of 614 patients, randomized participants 2:1 to receive either 15 mg of upadacitinib daily or a placebo. By the 48-week mark, the outcomes were statistically significant across multiple metrics. In Viti-Up-1, 19% of those on the medication achieved a 50% reduction in total-body vitiligo area scoring index (T-VASI50), compared with just 6% in the placebo group. The results in Viti-Up-2 were similarly aligned, with 21% of the treatment group reaching that same threshold. Facial repigmentation proved even more responsive, with 25% of patients in Viti-Up-1 hitting the 75% facial clearance goal (F-VASI75), a stark contrast to the 6% rate seen in the placebo arm.

Understanding the Clinical Boundaries of Repigmentation

While these numbers suggest a genuine breakthrough, the researchers were careful to highlight where the drug’s current efficacy hits a ceiling. Notably, T-VASI75—a more rigorous bar for total-body clearance—did not show a significant separation from the placebo in either trial. This suggests that while upadacitinib excels at facial repigmentation, it struggles to achieve the same level of success on the trunk and limbs within the 48-week window. Furthermore, the study authors acknowledged that the process of repigmentation had not yet plateaued by the end of the 48 weeks, meaning the long-term potential of the drug remains an open question that will require further observation.

The safety profile of the drug also invites a nuanced conversation for clinicians and payers. Treatment-emergent adverse events were more common in the upadacitinib groups, with reports of acne, headache, nasopharyngitis, and upper respiratory tract infections appearing more frequently than in the placebo cohorts. However, the trial did not record major adverse cardiovascular events, gastrointestinal perforations, or cases of lymphoma during the 48-week period. As the investigators noted, these findings are largely consistent with the safety profile already documented for upadacitinib in its existing FDA-approved uses for conditions like atopic dermatitis and alopecia areata.

The Economic and Regulatory Road Ahead

For the managed care sector, these results initiate a conversation that has not previously existed for the vitiligo community. Because upadacitinib is currently being studied as a monotherapy, the trials do not provide evidence on how the drug interacts with phototherapy or other common vitiligo treatments. This limitation, combined with the fact that patients with higher Fitzpatrick skin types were underrepresented in the study, leaves gaps that will likely need to be addressed during the regulatory review process. These variables are critical, as they influence both the generalizability of the results and the eventual formulary decisions that will determine patient access.

New trials for pill to treat skin pigment condition Vitiligo | 9 News Australia

“Upadacitinib 15 mg daily provides clinically meaningful repigmentation of both the face and total body for adults and adolescents with nonsegmental vitiligo, with no new safety signals identified,” the researchers stated in their findings, as published in The Lancet.

The medical community is also watching the broader field of JAK inhibitors closely. Recent reporting in Nature highlights a dense web of industry collaborations, with numerous researchers involved in vitiligo trials serving as consultants or investigators for a wide range of pharmaceutical companies. This underscores the intense competitive interest in finding a systemic solution for vitiligo, a disease where the psychosocial impact often disproportionately affects patients’ quality of life. Whether upadacitinib will become a standard tool in the dermatologist’s kit depends now on how these phase 3 results hold up under the scrutiny of regulatory bodies and the practical realities of long-term, real-world clinical application.

As the data from the Viti-Up trials moves toward formal review, the focus for clinicians remains on balancing the promise of clear clinical evidence against the necessity of long-term safety monitoring. For now, the findings offer the first systemic evidence of its kind, shifting the conversation from what is possible in a laboratory to what might soon be possible in a clinic.

Keep reading